Authors of the MEASURE 3 study have shared their end‐of‐study 3‐year efficacy and safety results of secukinumab, 150 mg and 300 mg, among patients with active ankylosing spondylitis. Find out what the...
After the agent did not have a significant effect on the primary end point in a previous phase 3 trial, researchers used a secondary end point from that trial as the primary end point of a new phase 3...
The ACR, SAA, and SPARTAN released an updated guideline for the management of AS and axial SpA that provides an overview of new treatment options and the use of imaging.
Since ankylosing spondylitis can impact individuals who are of working age, researchers sought to determine the disease’s impact on overall work stability.
Rheumatologists and oncologists should work together to develop treatment plans for patients with cancer experiencing inflammatory responses from immune checkpoint inhibitors.
